ArticleFrontiers in neurology2021

Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.

Cecilia Smith Simonsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.